Abbott Laboratories $ABT Shares Purchased by Diversified Portfolios Inc.

Diversified Portfolios Inc. grew its position in shares of Abbott Laboratories (NYSE:ABT) by 14.2% during the second quarter, Holdings Channel reports. The firm owned 4,098 shares of the healthcare product maker’s stock after acquiring an additional 509 shares during the quarter. Diversified Portfolios Inc.’s holdings in Abbott Laboratories were worth $557,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Purus Wealth Management LLC boosted its holdings in Abbott Laboratories by 3.8% during the 2nd quarter. Purus Wealth Management LLC now owns 6,632 shares of the healthcare product maker’s stock valued at $902,000 after acquiring an additional 240 shares during the period. United Advisor Group LLC boosted its stake in shares of Abbott Laboratories by 9.9% in the second quarter. United Advisor Group LLC now owns 2,332 shares of the healthcare product maker’s stock valued at $317,000 after purchasing an additional 210 shares during the period. First American Trust FSB grew its holdings in shares of Abbott Laboratories by 0.6% in the second quarter. First American Trust FSB now owns 113,885 shares of the healthcare product maker’s stock valued at $15,489,000 after purchasing an additional 670 shares in the last quarter. Empowered Funds LLC increased its stake in Abbott Laboratories by 100.1% during the 2nd quarter. Empowered Funds LLC now owns 101,476 shares of the healthcare product maker’s stock worth $13,802,000 after buying an additional 50,752 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.2%

Shares of NYSE ABT opened at $130.29 on Tuesday. The stock has a market cap of $226.55 billion, a PE ratio of 16.33, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The business has a 50-day moving average price of $130.34 and a 200 day moving average price of $131.35. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were given a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend was Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Analyst Ratings Changes

Several equities analysts have commented on ABT shares. Daiwa Capital Markets boosted their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 21st. Raymond James Financial boosted their target price on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Jefferies Financial Group increased their price target on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. The Goldman Sachs Group lifted their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.